Effectiveness of Rifabutin-Based Therapy for Helicobacter Pylori Infection
Author Information
Author(s): José M Navarro-Jarabo, Nuria Fernández, Francisca L Sousa, Encarnación Cabrera, Manuel Castro, Luz M Ramírez, Robin Rivera, Esther Ubiña, Francisco Vera, Isabel Méndez, Francisco Rivas-Ruiz, José L Moreno, Emilio Perea-Milla
Primary Institution: Unidad de Aparato Digestivo, Hospital Costa del Sol, Marbella, Spain
Hypothesis
Is a rifabutin-based treatment as effective as quadruple therapy for Helicobacter pylori infection?
Conclusion
Rifabutin-based therapy was not effective as a second-line treatment for Helicobacter pylori infection compared to quadruple therapy.
Supporting Evidence
- 70.4% eradication rate in the quadruple therapy group.
- 44.4% eradication rate in the rifabutin-based therapy group.
- 64% of patients in the quadruple therapy group reported adverse effects.
Takeaway
The study tested a new treatment for a stomach bug called Helicobacter pylori, but it didn't work as well as the old treatment.
Methodology
Randomized, multi-centre clinical trial comparing rifabutin-based therapy to conventional quadruple therapy over 7 days.
Potential Biases
Potential bias in randomization due to unequal distribution of ulcerous patients.
Limitations
The study had a small sample size and did not perform antibiogram studies before inclusion.
Participant Demographics
Patients with Helicobacter pylori infection who failed first-line treatment, aged 18-75.
Statistical Information
P-Value
0.009
Confidence Interval
1.1–2.29
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website